|1.||Kido, Momoko: 1 article (10/2015)|
|2.||Kakimi, Kazuhiro: 1 article (10/2015)|
|3.||Fujita, Kana: 1 article (10/2015)|
|4.||Hosoi, Akihiro: 1 article (10/2015)|
|5.||Nonomura, Hidenori: 1 article (10/2015)|
|6.||Uenaka, Akiko: 1 article (10/2015)|
|7.||Matsushita, Hirokazu: 1 article (10/2015)|
|8.||Mandai, Komako: 1 article (10/2015)|
|9.||Fujieda, Nao: 1 article (10/2015)|
|10.||Atago, Yuki: 1 article (10/2015)|
08/01/1979 - "The application of the method for studies on the generation of immunoresistant tumor cell variants and on the relationship between antibody-binding sites and rejection target sites is discussed."
02/01/1989 - "As reported previously, 3A4 is a paratope-specific anti-idiotypic mAb and induces cellular and humoral anti-tumor-associated Ag (TAA) responses. "
07/01/2014 - "Knowledge about the epitope/paratope interface opens new avenues for the study of tumor sensitivity/resistance to nimotuzumab and for further engineering of its binding site. "
02/01/1985 - "The number of antibody-binding sites per cell on the tumor cell surface was significantly higher for tumoricidal MAb as compared to unreactive MAb. On the other hand, the percentage of tumor cells binding the MAb and the binding affinity to these cells were the same for the two groups of MAb. Also, tumoricidal and nontumoricidal MAb bound with similar affinity and antibody density to Fc receptors on macrophages. "
02/01/1987 - "Finally, using iodine-125 labeled preparations of purified Lym-1 and Lym-2, we have determined that both reagents have a relatively large number of antibody binding sites per tumor cell and increased avidity for lymphoma cells when compared to normal and reactive lymph node B-cells.(ABSTRACT TRUNCATED AT 400 WORDS)"
01/01/2013 - "In this study, we examined the antibody-binding site of SPE B and used it to block SPE B actions during GAS infection. "
07/01/2000 - "In addition to being highly expressed (approximately 1000-7000 STRL33 ABS [antibody binding sites]) on specific subsets of natural killer cells (CD3(-)/CD16(-/low)/CD56(+) and CD3(-)/CD16(low)/CD56(-)) and CD19(+) B lymphocytes (approximately 300-5000 STRL33 ABS), STRL33 was expressed at levels sufficient to support virus infection on freshly isolated, truly naive CD4(+)/CD45RA(+)/CD62L(+) cells (6000-11 000 ABS). "
04/01/1989 - "These results indicate that active immunization with a fusion protein containing the cross-reactive CTL epitope protects mice from influenza infection by inducing CTL against influenza A H1 and H2 subtype virus strains, which markedly vary in their antibody binding sites on the HA1. "
12/01/2008 - "This study provides insights on the paratope-epitope interaction and can be used to identify compounds with comparable properties as the paratope leading to future development of drugs and vaccines for WSSV infection."
01/01/2013 - "Determining antibody-binding site of streptococcal pyrogenic exotoxin B to protect mice from group a streptococcus infection."
|4.||Typhoid Fever (Typhoid)
11/01/2003 - "Binding of MAb ATVi to the mimotopes was specifically blocked by ViCPS, indicating that they interact with the same binding site (paratope) of the MAb. Data and reagents generated in this study have important implications for the development of peptide-base diagnostic tests and peptide vaccines and may also provide a better understanding of the pathogenesis of typhoid fever."
07/20/1993 - "A partially protective effect of the antibodies against amanitin toxicity in vitro in Chang cells was evident at a molar ratio of antibody binding sites to alpha-amanitin of 4:1. Together with reported studies in vivo, these investigations indicate the potential of immunotherapy for amanitin poisoning."
|4.||Indicators and Reagents (Reagents)
|9.||bovine (152-168) serum albumin (ABBOS)
|2.||Transplantation (Transplant Recipients)